An interventional study of Absorb and Desolve in Coronary Artery Disease, sponsored by Aarhus University Hospital Skejby. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby — none open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Aarhus University Hospital Skejby.
Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 with no phase, and was the 12th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →None of the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby is open now. The open studies under Coronary Artery Disease, anywhere →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2016.
This study's planned enrollment of 120 is close to the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 425 across the 15 interventional studies, 329 across the 3 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.
1 of the studies in Coronary Artery Disease by Aarhus University Hospital Skejby that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02973529Aarhus University Hospital SkejbyThe Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Coronary artery disease is often treated by implantation of permanent metallic stents.Coronary stents are required in the early healing phase after balloon dilatation but constitute a lifelong foreign body. New bioresorbable stents have been developed and are believed to improve long-term safety. The purpose of this study is to compare the safety and vessel healing after treatment of simple bifurcation lesions with the CE-marked bioresorbable stents Absorb and Desolve.
BIFSORB is a prospective, randomized multicenter trial comparing 6-month healing outcome after treatment of simple coronary bifurcation lesions by Absorb or Desolve BRS. for treatment of coronary bifurcation lesions.
BRS are promising in treatment of coronary artery disease. The concept of bifurcation treatment using BRS is particular appealing as struts covering the side branch ostium may resorb over time.
The aim of this study is to compare the 6 months safety and vessel healing after treatment of coronary bifurcation lesions by the Desolve or Absorb BRS.
Hypothesis: Treatment of coronary bifurcation lesions using Absorb and Desolve bioresorbable stents is safe. Treatment of coronary bifurcation lesions by Desolve BRS is associated with a lower index of adverse vessel wall features (main vessel area stenosis, acquired malapposition, evaginations, late recoil, single end attached protruding struts, side branch ostial area stenosis) at 6 months compared to treatment with Absorb BRS.
Methods:
Prospective, open label, single blind, randomized, feasibility and safety pilot study with inclusion of 120 patients. Randomization 1:1 to Absorb or Desolve. Planned 6- and 24-month follow-up by OCT and follow-up for clinical endpoints until 10 years.
Eligible patients with a bifurcation lesion are treated by the provisional technique with mandatory jailing of the side branch and provisional opening of side branch ostium by the mini-kiss technique in case of severe pinching or TIMI-flow less than III. Proximal post-dilatation is mandatory. No dilatation beyond the expansion limits of the BRS.
The patients are assessed by optical coherence tomography (OCT) before, during and after implantation of the Absorb or Desolve BRS at baseline procedure and again at 6- and 24-month follow-up, or before if they are readmitted with a possible target lesion failure.
The operator is not blinded to pre-PCI OCT images that may be used for sizing and positioning of the scaffolds. Procedural OCT may be used to optimize scaffold implantation before performing final OCT.
Results are reported as clinical safety at 6 months (myocardial infarction, revascularization, death) and stent healing index by OCT including malapposition, stent coverage, side branch ostial area late loss, fracture and evaginations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomization to implantation of Absorb BVS in bifurcation lesion
Device: Absorb
Randomization to implantation of Desolve BRS in bifurcation lesion
Device: Desolve
Randomization to implantation of Absorb BVS in bifurcation lesion
Randomization to implantation of Desolve BRS in bifurcation lesion
Number of participants with Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.
Clinical safety measured as: major procedural myocardial infarction, non-procedural target vessel myocardial infarction, target lesion failure, cardiac death.
Time frame: 6 months
Index of adverse vessel wall features
Side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain
Time frame: 6 months
Optical coherence tomography endpoint: acute malapposition
Time frame: Baseline
Optical coherence tomography endpoint: acquired malapposition
Time frame: 6 and 24 months
Optical coherence tomography endpoint: persistent malapposition
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Coverage of jailing struts
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Extra stent lumen (including evaginations)
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Late stent recoil
Time frame: 6 and 24 months
Optical coherence tomography endpoint: stent fracture
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Ostial strut loss
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Mean neointimal thickness
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Stent strut coverage
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Minimal luminal area in segmental analysis
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Minimal stent area in segmental analysis
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Minimum scaffold expansion area %
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Segmental area stenosis
Time frame: Baseline, 6 and 24 months
Optical coherence tomography endpoint: Healing above calcified plaque
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Healing above lipid plaque
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Acute thrombus on struts
Time frame: Baseline
Optical coherence tomography endpoint: Late thrombus on struts
Time frame: 6 and 24 months
Optical coherence tomography endpoint: Acute expansion
Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation
Time frame: Baseline
Optical coherence tomography endpoint:Late recoil
Measured in segments with; 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation
Time frame: 6 and 24 months
Angiographic endpoint: Ostial side branch area stenosis
Time frame: Baseline, 6 and 24 months
Angiographic endpoint: Ostial side branch acute gain after main vessel stenting
Time frame: Baseline
Angiographic endpoint: Ostial side branch late loss
Time frame: 6 and 24 months
Angiographic endpoint: Ostial distal main vessel area stenosis
Time frame: Baseline, 6 and 24 months
Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting
Time frame: Baseline
Angiographic endpoint: Ostial distal main vessel late loss
Time frame: 6 and 24 months
Angiographic endpoint: Proximal main vessel area stenosis
Time frame: Baseline, 6 and 24 months
Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting
Time frame: Baseline
Angiographic endpoint: Proximal main vessel late loss
Time frame: 6 and 24 months
Angiographic endpoint: Minimal luminal area of all segments
Time frame: Baseline, 6 and 24 months
Procedural endpoints: Procedure time
From sheath insertion to closure device excluding treatment of other vessels
Time frame: Baseline
Procedural endpoints: Contrast use
Time frame: Baseline
Procedural endpoints: Fluoroscopy time
Time frame: Baseline
Clinical endpoints: Myocardial infarction
Time frame: 10 years
Clinical endpoints: Target lesion failure
Time frame: 10 years
Clinical endpoints: Target lesion revascularization
Time frame: 10 years
Clinical endpoints: Stent thrombosis
Time frame: 10 years
Clinical endpoints: Cardiac death
Time frame: 10 years
Clinical endpoints: Non-Cardiac death
Time frame: 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jan 2016, a primary completion of Nov 2026 and a completion of Sep 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital Skejby